These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 16267526)

  • 1. Race is on for flu vaccine.
    Wadman M
    Nature; 2005 Nov; 438(7064):23. PubMed ID: 16267526
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccines for seasonal and pandemic influenza.
    Nichol KL; Treanor JJ
    J Infect Dis; 2006 Nov; 194 Suppl 2():S111-8. PubMed ID: 17163383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AS03-adjuvanted influenza vaccine in elderly people.
    Ledgerwood JE
    Lancet Infect Dis; 2013 Jun; 13(6):466-7. PubMed ID: 23518157
    [No Abstract]   [Full Text] [Related]  

  • 4. MF59 adjuvant: the best insurance against influenza strain diversity.
    O'Hagan DT; Rappuoli R; De Gregorio E; Tsai T; Del Giudice G
    Expert Rev Vaccines; 2011 Apr; 10(4):447-62. PubMed ID: 21506643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.
    Black S; Della Cioppa G; Malfroot A; Nacci P; Nicolay U; Pellegrini M; Sokal E; Vertruyen A
    Vaccine; 2010 Oct; 28(45):7331-6. PubMed ID: 20813217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
    El Sahly H
    Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months.
    Esposito S; Pugni L; Daleno C; Ronchi A; Valzano A; Serra D; Mosca F; Principi N
    Pediatrics; 2011 May; 127(5):e1161-8. PubMed ID: 21464195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
    Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
    Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals.
    Kajaste-Rudnitski A; Galli L; Nozza S; Tambussi G; Di Pietro A; Pellicciotta G; Monti A; Mascagni P; Moro M; Vicenzi E
    AIDS; 2011 Jan; 25(2):177-83. PubMed ID: 21150561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses.
    Beran J; Abdel-Messih IA; Raupachova J; Hobzova L; Fragapane E
    Clin Ther; 2010 Dec; 32(13):2186-97. PubMed ID: 21316535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients.
    Kumar D; Campbell P; Hoschler K; Hidalgo L; Al-Dabbagh M; Wilson L; Humar A
    Transplantation; 2016 Mar; 100(3):662-9. PubMed ID: 26335915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection bias in the comparison between adjuvanted and unadjuvanted influenza vaccine effectiveness.
    De Serres G
    Vaccine; 2014 Nov; 32(49):6596. PubMed ID: 24380683
    [No Abstract]   [Full Text] [Related]  

  • 16. MF59™-adjuvanted seasonal influenza vaccine in young children.
    Puig-Barberà J; Pérez-Vilar S; Díez-Domingo J
    Expert Rev Vaccines; 2011 Nov; 10(11):1519-28. PubMed ID: 22043952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and effectiveness of MF-59 adjuvanted influenza vaccines in children and adults.
    Black S
    Vaccine; 2015 Jun; 33 Suppl 2():B3-5. PubMed ID: 26022564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply to letter to the editor.
    Van Buynder PG
    Vaccine; 2015 Mar; 33(10):1234. PubMed ID: 25620246
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus.
    Zuccotti GV; Pariani E; Scaramuzza A; Santoro L; Giani E; Macedoni M; Gazzarri A; Anselmi G; Amendola A; Zanetti A
    Diabet Med; 2011 Dec; 28(12):1530-6. PubMed ID: 21916971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.